Distinct Genomic and Epigenetic Drivers in IDH-Mutant and IDH-Wildtype Astrocytomas: Implications for Prognosis and Therapy

Cytogenetically, IDH-mutant tumors generally demonstrate a lower frequency of the classical +7/−10 whole-chromosome signature and EGFR amplification that typify IDH-wildtype glioblastoma. However, as they progress to grade 4, they accumulate focal Copy Number Variations (CNVs) and region-level aneuploidy (including chromosome 9p loss), producing an elevated copy-number burden and subclonal chromosomal instability in many cases [28, 30]. Functionally, these chromosomal events translate into predictable protein-level consequences, including CDKN2A/B loss, which causes loss of p16 ^INK4a and p14 ^ARF protein expression with resultant unchecked CDK4/6–RB pathway activity and impaired p53-mediated checkpoints. Second, ATRX loss associates with perturbation of chromatin remodeling and Alternative Lengthening of Telomeres (ALT) phenotypes; MDM2/MDM4 alterations blunt p53 signaling, and CDK4/CCND2 amplifications increase cyclin-dependent kinase activity — all changes readily detectable by immunohistochemistry or proteomic profiling and concordant with the underlying CNV landscape [26, 27]. Mechanistically, mutant IDH enzymes (typically IDH1 R132H) produce the oncometabolite D-2-hydroxyglutarate (2HG). This metabolite competitively inhibits α-ketoglutarate-dependent dioxygenases, including Ten-Eleven Translocation (TET) DNA demethylases and histone lysine demethylases, resulting in widespread epigenetic reprogramming and the establishment of a glioma-CpG island methylator phenotype (G-CIMP). Such epigenetic remodeling has been shown to alter chromatin architecture and increase heterochromatin-associated replication stress, which slows replication fork progression and promotes DNA damage accumulation during tumor evolution. Recent mechanistic studies further indicate that oncogenic IDH mutations promote heterochromatin-mediated replication stress without completely abolishing homologous recombination (HR) repair, thereby creating genomic conditions favorable for the gradual accumulation of copy-number alterations and chromosomal instability in glioma cells [31]. Consequently, persistent replication stress and impaired DNA damage responses facilitate the accumulation of double-strand DNA breaks and suboptimal repair processes, ultimately promoting chromosomal instability (CIN) and aneuploidy during astrocytoma progression. However, 2HG-mediated homologous recombination (HR) defects and replication stress not only contribute to the emergence of copy number variations (CNVs), such as CDKN2A/B loss, during malignant progression, but also create exploitable therapeutic vulnerabilities. These include increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, as well as strategies targeting replication stress and cell-cycle checkpoints. Additionally, these alterations provide a rationale for CDK4/6 inhibition in tumors harboring CDKN2A/B loss or CDK4 amplification, which are currently under active preclinical and clinical investigation [32, 33]. These changes, influenced in part by IDH-mutation-mediated epigenetic and replication perturbations [13, 34], drive malignant progression across the diffuse glioma spectrum and support the development of highly aggressive glioma states, including glioblastoma [6, 35], as illustrated in Figure 2A,B. Consistent with recent integrative genomic analyses of glioma evolution, the accumulation of focal CNVs, chromosomal alterations, and epigenetically driven genomic instability represents a key molecular mechanism underlying the progression of lower-grade IDH-mutant astrocytomas toward higher-grade disease states [34]. Taken together, the genomic architecture of astrocytoma, IDH-mutant, WHO grade 4 reflects progressive chromosomal instability and accumulation of focal copy-number alterations during tumor evolution. Hence, documenting these genomic and proteomic changes is critical for accurate WHO grading, prognosis, and for selecting targeted therapeutics.

Although IDH-mutant astrocytoma harbors a broad range of genomic instability, it exhibits distinct metabolic weaknesses stemming from disrupted Tricarboxylic Cycle Acid (TCA) cycle activity, reduced proliferation rates, and modified cellular metabolism [36]. As a result, IDH-mutant is associated with a better prognosis compared to its counterpart, IDH-wildtype, and is considered a decisive marker for secondary GBMs [37]. Unlike secondary glioblastomas, primary glioblastomas, which are largely IDH-wildtype, are cytogenetically distinguished by recurrent large-scale chromosomal abnormalities, most notably gain of chromosome 7 and loss of chromosome 10 (+7/−10), a characteristic aneuploidy signature observed in the majority of tumors [38] (Figure 2C). Alternatively termed, IDH-wildtype diffuse astrocytic tumors constitute the most aggressive category of adult-type diffuse gliomas. According to the 2021 WHO Classification of Tumors of the Central Nervous System (CNS5), these tumors are classified as glioblastoma, IDH-wildtype, CNS WHO grade 4, which exhibit defined molecular criteria, including TERT promoter mutation, EGFR amplification, or the combined whole-chromosome +7/−10 signature even in the absence of grade-4 histological characteristics [20]. Molecularly, these tumors display extensive chromosomal instability (CIN) and widespread aneuploidy accompanied by focal genomic alterations affecting major oncogenic signaling pathways. Recurrent events include EGFR amplification (7p11.2), MDM2 and CDK4 co-amplification (12q13-15), Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) amplification (4q12), Phosphatase and Tensin Homolog (PTEN) loss or mutation (10q23.31), CDKN2A/B homozygous deletion (9p21.3), and RB1 deletion (13q14), which collectively reshape oncogenic signaling networks and drive tumor progression [5, 22, 39].

These large-scale chromosomal aberrations drive oncogenic signaling, disrupt cell-cycle checkpoints, and alter the proteomic landscape of tumor cells. For instance, EGFR amplification results in overexpression and constitutive activation of EGFR protein and downstream PI3K–AKT–mammalian target of Rapamycin (mTOR) and RAS/Rapidly Accelerated Fibrosarcoma/Mitogen-Activated Protein Kinase (RAS–RAF–MAPK) cascades, associated with cellular proliferation, metabolic adaptation, and survival signaling [40]. Concurrently, PTEN loss eliminates a critical negative regulator of PI3K signaling, further amplifying oncogenic pathway activity and contributing to tumor growth and therapy resistance [41]. Similarly, CDKN2A/B deletion leads to reduced p16 ^INK4a and p14 ^ARF expression, thereby releasing inhibition on CDK4/6–RB and p53 pathways, respectively, further enabling cell-cycle progression and genomic instability [34]. In addition to focal alterations, the characteristic +7/−10 chromosomal signature alters gene dosage across numerous genomic loci and has been associated with increased mitotic activity, intratumoral heterogeneity, and resistance to therapy [38]. Collectively, these chromosomal and proteomic alterations define the aggressive biology of IDH-wildtype astrocytic tumors, linking CIN-driven aneuploidy to poor prognosis and underscoring the need for therapies targeting mitotic fidelity, replication stress, and EGFR/PI3K signaling dependencies [19, 42]. Integration of chromosomal alterations with molecular biomarkers and epigenetic features (Table 1) therefore, improves diagnostic precision and prognostic stratification in patients with IDH-wildtype glioblastoma [43]. Therapies targeting other critical pathways, such as the TGF-beta signaling pathway , are also under investigation.

Molecular Prognostic Markers in Glioblastoma